Muscle-Invasive Bladder Cancer: Difference between revisions

Line 101:

*'''CUA (HE 2 NICE)'''

** '''Absolute (6):'''

**# '''≥Grade 2 Hearing loss''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)

**# '''≥Grade 2 Hearing loss''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)

**# '''~~eGFR~~ ≤ 50''' ml/min/1.73m2

**# '''eGFR ≤ 50''' ml/min/1.73m2

**# '''≥Grade 2 ~~Neuropathy~~''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)

**# '''≥Grade 2 Neuropathy''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)

**# '''Untreated Infection'''

**# '''Cardiac failure (NYHA Class > 2)'''

@@ Line 101: / Line 101: @@
 *'''CUA (HE 2 NICE)'''
 ** '''<span style="color:#ff0000">Absolute (6):</span>'''
-**# '''<span style="color:#ff0000">≥Grade </span>2 <span style="color:#0000ff">H</span><span style="color:#ff0000">earing loss</span>''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)
+**# '''<span style="color:#ff0000">≥Grade </span><span style="color:#0000ff">2 H</span><span style="color:#ff0000">earing loss</span>''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)
-**# '''<span style="color:#ff0000">eGFR ≤ 50</span>''' ml/min/1.73m2
+**# '''<span style="color:#0000ff">e</span><span style="color:#ff0000">GFR ≤ 50</span>''' ml/min/1.73m2
-**# '''<span style="color:#ff0000">≥Grade </span>2 Neuropathy</span>''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)
+**# '''<span style="color:#ff0000">≥Grade </span><span style="color:#0000ff">2 N</span><span style="color:#ff0000">europathy</span>''' (grading based on Common Terminology Criteria for Adverse Events version 4.0)
 **# '''<span style="color:#ff0000">Untreated </span>I</span>nfection</span>'''
 **# '''<span style="color:#ff0000">C</span>ardiac failure (NYHA Class > </span>2)</span>'''